Brief: Neurocrine Biosciences And Sosei Heptares Announce Collaboration To Develop Novel Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders

Nxera Pharma

22/11/2021 16:59

Nov 22 (Reuters) - Neurocrine Biosciences Inc  NBIX.O :
    * NEUROCRINE BIOSCIENCES AND SOSEI HEPTARES ANNOUNCE
COLLABORATION
TO DEVELOP NOVEL MUSCARINIC RECEPTOR AGONISTS FOR SCHIZOPHRENIA
AND OTHER NEUROPSYCHIATRIC DISORDERS
    * NEUROCRINE BIOSCIENCES INC - SOSEI HEPTARES RECEIVES
US$100
MILLION UPFRONT
    * NEUROCRINE BIOSCIENCES - DEAL FOR UP TO US$2.6 BILLION IN
POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE
PAYMENTS, PLUS TIERED SALES ROYALTIES
    * NEUROCRINE BIOSCIENCES INC - ANTICIPATES INITIATING A
PHASE 2
STUDY WITH SELECTIVE M4 AGONIST HTL-0016878 IN SCHIZOPHRENIA IN
2022
    * NEUROCRINE BIOSCIENCES INC - ANTICIPATES PHASE 1 STUDIES
FOR A
DUAL M1/M4 AND SELECTIVE M1 AGONIST IN 2023
    * NEUROCRINE BIOSCIENCES - WILL BE RESPONSIBLE FOR
DEVELOPMENT
COSTS ASSOCIATED WITH PROGRAMS GLOBALLY, EXCEPT FOR M1 AGONISTS
BEING DEVELOPED IN JAPAN

Source text for Eikon:  ID:nPn62X1tTa 
Further company coverage:  NBIX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))